| Literature DB >> 27218821 |
Myung-Sun Kim1,2,3, Ji Hea Yu2,3,4, Min-Young Lee2,3, Ah Leum Kim5, Mi Hyun Jo1,5, MinGi Kim2,3,4, Sung-Rae Cho2,3,4, Young-Han Kim1,5.
Abstract
Preeclampsia is a common disease that can occur during human pregnancy and is a leading cause of both maternal and neonatal morbidity and mortality. Inadequate trophoblast invasion and deficient remodeling of uterine spiral arteries are associated with preeclampsia (PE). The development of this syndrome is thought to be related to multiple factors. Recently, we isolated patient-specific human amniotic epithelial cells (AECs) from the placentas of 3 women with normal pregnancy and 3 with preeclamptic pregnancy. Since the characteristics of human AECs in PE are different from those in normal pregnancy, we sought to confirm the genes differentially expressed between preeclamptic pregnancy and normal pregnancy. Therefore, we performed transcriptome analysis to investigate the candidate genes associated with the possible pathophysiology of preeclampsia. Pathway analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) and Kyoto Encyclopedia of Genes and Genomes (KEGG) online resource. In this study, we selected a total of 12 pathways and focused on extracellular matrix-related and biological adhesion molecules. Using RT-PCR array and real-time PCR, we confirmed that COL16A1, ITGB2, and LAMA3 were significantly up-regulated, but ITGA1, ITGA3, ITGA6, MMP1, MMP3, MMP10 and MMP11 were significantly down-regulated in preeclamptic fetal origin cells. Taken together, we suggest that the genes and pathways identified here may be responsible for the occurrence and development of PE, and controlling their expression may play a role in communication with fetal-maternal placenta to keep normal pregnancy.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27218821 PMCID: PMC4878795 DOI: 10.1371/journal.pone.0156038
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical Characteristics of Participants.
| Maternal age (years) | Gestational age (weeks) | Height (cm) | PP weight (Kg) | Weight at admission (Kg) | BMI (PP/admission) (kg/m2) | BP at admission (mmHg) | Proteinuria | Gravida | Birth weight (g) | AS(1) | AS(5) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal 1 | 28 | 38 | 158 | 57 | 75 | 22.8/30.0 | 120/80 | negative | 1 | 3190 | 5 | 9 |
| Normal 2 | 34 | 38 | 163 | 63 | 64 | 23.7/24.0 | 102/77 | negative | 2 | 3180 | 7 | 8 |
| Normal 3 | 38 | 38 | 158 | 77 | 87 | 30.8/34.8 | 125/70 | negative | 4 | 3560 | 7 | 9 |
| Preeclampsia 1 | 29 | 35 | 166 | 51 | 65 | 18.5/23.5 | 170/100 | 2+ | 1 | 1710 | 7 | 8 |
| Preeclampsia 2 | 37 | 34 | 158 | 43 | 58 | 17.2/23.2 | 150/90 | 3+ | 6 | 2300 | 6 | 7 |
| Preeclampsia 3 | 39 | 32 | 163 | 70 | 78 | 26.3/29.3 | 160/100 | 1+ | 2 | 1400 | 5 | 7 |
PP, pre-pregnant; BMI, body mass index; BP, blood pressure; AS, Apgar score
Fig 1The characteristics of fetal origin AECs. Scale bar = 50μm.
(A) Fetal origin AECs from a healthy pregnant woman, and a pregnant woman with PE. AECs marker cytokeratin-7 was visualized by Alexa Fluor® 488 goat anti-Rabbit secondary antibody (green). And nuclei were counter stained with 4’,6-diamidino-2-phenylindole (DAPI). (B) RT-QPCR analysis was used to determine Oct4, Nanog, and Sox-2, which are indicating their stem-like potential. (lane 1, human fibroblast as a negative control; lane 2–4, normal AECs; lane 5–7, patient AECs; and lane 8, iPSC from normal AECs). RT-QPCR was performed 35 cycles, and GAPDH was used as the internal control, and performed 25 cycles.
Fig 2Gene-ontology analysis of DEGs between PE and normal pregnancy.
(A) Main categories of increased or decreased genes in PE on the basis of their cellular components. (B) Main categories of increased or decreased genes in PE on the basis of their biological processes. The numbers indicate involved genes. (F-statistic p<0.05).
Pathways associated with preeclampsia subjects generated by DAVID.
| Term | Count | % | P Value | Genes |
|---|---|---|---|---|
| hsa04512:ECM-receptor interaction | 18 | 0.27 | 1.40E-07 | ITGA11, ITGB4, ITGA1, ITGB5, COL5A3, SDC4, HMMR, LAMA2, LAMB3, LAMA3, ITGA6, ITGB6, COL6A3, COL6A2, COL6A1, LAMC2, THBS2, COL11A1 |
| hsa04510:Focal adhesion | 27 | 0.41 | 9.30E-07 | ITGA11, ITGB4, ITGB5, LAMB3, ITGB6, COL6A3, COL6A2, COL6A1, PDGFD, THBS2, COL11A1, SHC4, FLT1, ITGA1, COL5A3, FLNB, LAMA2, LAMA3, CCND3, ITGA6, CCND2, FYN, MAPK3, VEGFA, PDGFRA, LAMC2, MAPK8 |
| hsa05410:Hypertrophic cardiomyopathy (HCM) | 13 | 0.20 | 4.00E-04 | PRKAB2, ITGA11, ITGB4, ITGA1, ITGB5, TPM2, TPM4, LAMA2, TNNT2, ACE, DES, ITGA6, ITGB6 |
| hsa03320:PPAR signaling pathway | 10 | 0.15 | 0.004 | OLR1, SCD, FABP3, SLC27A6, FABP4, SCD5, PCK2, ACSL3, MMP1, PLTP |
| hsa04350:TGF-beta signaling pathway | 11 | 0.17 | 0.006 | PPP2R1B, BMP2, LTBP1, CDKN2B, INHBE, ID1, MAPK3, GDF5, DCN, THBS2, BMP6 |
| hsa05412:Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 10 | 0.15 | 0.007 | LAMA2, DES, DSG2, ITGA6, PKP2, ITGB6, ITGA1, ITGB4, ITGA11, ITGB5 |
| hsa05414:Dilated cardiomyopathy | 11 | 0.17 | 0.008 | TNNT2, LAMA2, DES, ITGA6, ITGB6, ITGA1, ITGB4, ITGA11, ITGB5, TPM2, TPM4 |
| hsa05219:Bladder cancer | 7 | 0.11 | 0.011 | TYMP, CDKN1A, CDKN2A, MAPK3, VEGFA, CDH1, MMP1 |
| hsa04115:p53 signaling pathway | 9 | 0.14 | 0.011 | STEAP3, CDKN1A, CDKN2A, TNFRSF10B, CCND3, CCND2, BBC3, SFN, CDK2 |
| hsa04514:Cell adhesion molecules (CAMs) | 12 | 0.18 | 0.037 | F11R, CLDN7, CLDN4, PTPRF, ITGA6, CLDN6, CLDN1, CDH1, L1CAM, VCAN, CLDN11, SDC4 |
| hsa04614:Renin-angiotensin system | 4 | 0.06 | 0.039 | ACE, REN, MME, ANPEP |
| hsa05200:Pathways in cancer | 23 | 0.35 | 0.041 | BMP2, WNT5B, PTGS2, PML, FOXO1, CDH1, ZBTB16, CDK2, MMP1, FZD7, LAMA2, LAMB3, CDKN1A, CDKN2A, LAMA3, CDKN2B, ITGA6, VEGFA, MAPK3, PDGFRA, LAMC2, MAPK8, WNT6 |
These pathways are statistically significant (P-value < 0.05)
Fig 3Information regarding gene function using gene ontology from KEGG pathway database.
The numbers indicate involved genes. (F-statistic p<0.05).
Pathways upregulated in preeclampsia subjects generated by DAVID.
| Term | Count | % | P Value | Genes |
|---|---|---|---|---|
| hsa04512:ECM-receptor interaction | 14 | 0.34 | 7.83E-07 | ITGA11, ITGB4, COL5A3, SDC4, LAMA2, LAMB3, LAMA3, ITGB6, COL6A3, COL6A2, COL6A1, LAMC2, COL11A1, THBS2 |
| hsa04510:Focal adhesion | 17 | 0.41 | 2.47E-04 | FLT1, ITGA11, ITGB4, COL5A3, LAMA2, LAMB3, LAMA3, CCND3, FYN, ITGB6, COL6A3, COL6A2, COL6A1, LAMC2, PDGFD, COL11A1, THBS2 |
| hsa03320:PPAR signaling pathway | 8 | 0.19 | 0.004 | OLR1, SCD, FABP3, SLC27A6, SCD5, PCK2, ACSL3, PLTP |
| hsa05410:Hypertrophic cardiomyopathy (HCM) | 8 | 0.19 | 0.012 | TNNT2, LAMA2, ACE, DES, ITGB6, ITGB4, ITGA11, TPM4 |
| hsa04115:p53 signaling pathway | 7 | 0.17 | 0.014 | STEAP3, CDKN1A, CDKN2A, TNFRSF10B, CCND3, BBC3, SFN |
| hsa04514:Cell adhesion molecules (CAMs) | 10 | 0.24 | 0.015 | F11R, CLDN7, CLDN4, PTPRF, CLDN6, CLDN1, CDH1, L1CAM, CLDN11, SDC4 |
| hsa05412:Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 7 | 0.17 | 0.024 | LAMA2, DES, DSG2, PKP2, ITGB6, ITGB4, ITGA11 |
| hsa04350:TGF-beta signaling pathway | 7 | 0.17 | 0.043 | LTBP1, CDKN2B, INHBE, GDF5, DCN, THBS2, BMP6 |
These pathways are statistically significant (P-value < 0.05)
Pathways downregulated in preeclampsia subjects generated by DAVID.
| Term | Count | % | P Value | Genes |
|---|---|---|---|---|
| hsa04510:Focal adhesion | 10 | 0.37 | 0.007 | ITGA6, CCND2, MAPK3, VEGFA, PDGFRA, ITGA1, ITGB5, MAPK8, FLNB, SHC4 |
| hsa04910:Insulin signaling pathway | 7 | 0.26 | 0.027 | PRKAR2B, PHKG1, PRKAB2, MAPK3, FOXO1, MAPK8, SHC4 |
These pathways are statistically significant (P-value < 0.05)
Fig 4Validation for mRNA quantification of ECM-related and biological adhesion molecules.
(A) The relative expression levels for COL16A1, ITGB2, and LAMA3 were significantly up-regulated, but ITGA1, ITGA3, ITGA6, MMP-1, MMP-3, MMP-10 and MMP-11 were significantly down-regulated in AEC from patients with PE. (B) COL6A1, COL6A2, COL14A1, FN1, LAMA2, THBS2, and THBS3 were up- or down-regulated, but not significant in AEC from patients with PE.